Oxygen-Mediated Suppression of CD8+ T Cell Proliferation by Macrophages: Role of Pharmacological Inhibitors of HIF Degradation

Milos Gojkovic1, Pedro P. Cunha2, Gabriella S. Darmasaputra1, Laura Barbieri1, Helene Rundqvist2, Pedro Velica1 and Randall S. Johnson1,3*

1 Department of Cell and Molecular Biology, Karolinska Institute, Stockholm, Sweden, 2 Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden, 3 Department of Physiology Development and Neuroscience, University of Cambridge, Cambridge, United Kingdom

Myeloid cell interactions with cells of the adaptive immune system are an essential aspect of immunity. A key aspect of that interrelationship is its modulation by the microenvironment. Oxygen is known to influence myelosuppression of T cell activation in part via the Hypoxia inducible (HIF) transcription factors. A number of drugs that act on the HIF pathway are currently in clinical use and it is important to evaluate how they act on immune cell function as part of a better understanding of how they will influence patient outcomes. We show here that increased activation of the HIF pathway, either through deletion of the negative regulator of HIF, the von Hippel-Lindau (VHL) gene, in myeloid cells, or through pharmacological inhibitors of VHL-mediated degradation of HIF, potently suppresses T cell proliferation in myeloid cell/T cell culture. These data demonstrate that both pharmacological and genetic activation of HIF in myeloid cells can suppress adaptive cell immune response.

Keywords: Nitric oxide, hypoxia, immunosuppression, HIF, myeloid cells, von Hippel-Lindau, Prolyl hydroxylase inhibitors

INTRODUCTION

Oxygen availability is a critical factor in immune response (1). Each cell in the immune system has to carry out its functions in an environment marked by a specific level of oxygenation (2). As immune cells move through tissues, oxygen availability can rapidly change, and these cells thus need to be able to function in high or low oxygen environments (2).

The discovery of the HIF transcription factor, and the finding that HIF and hypoxic response are fundamental elements of immune cell function, has led to numerous important findings concerning the relationships between HIF and immunity (1, 3). These findings have primarily focused on individual cell types and their responses to hypoxia: studies have, for example, found important roles for HIF response in the innate immune system, including macrophages, neutrophils, and dendritic cells, as well as in adaptive immunity in B cells and CD4+ and CD8+ T cells (3–6).
With this understanding of how oxygenation and hypoxic response influences individual cells it becomes important to understand how these affect cell-cell interactions during immune response. One key finding in this regard was the demonstration that hypoxia can trigger myeloid suppression of T cell proliferation, and that this suppression requires activation of HIF-1α in myeloid cells (7).

Solid tumors often contain immunosuppressive microenvironments (8) characterized by cytokines (including IL10, IL6, galectin-1 and TGF-β) that are upregulated by hypoxia and HIF signaling (9, 10). PD-L1, a protein that blocks cytotoxic T cell function, shows increased expression in both tumor cells and myeloid cells and its expression is in part regulated by HIF-dependent pathways (10). Loss of myeloid HIF-1α results in impaired myeloid cell infiltration and inflammation (3, 11, 12) and decreased tumor progression in a spontaneous mammalian breast cancer model (7). Loss of myeloid HIF-2α has been linked to decreased tumor inflammation and progression in murine models of breast and gastric cancer (13, 14), while tumor-associated myeloid cells can also contribute to immune suppression by production of nitric oxide (NO), acting through the HIF-1α-NOS2 pathway (4, 7).

In this study, we examine the role of deregulated hypoxic response to determine in detail how key HIF-regulated myelosuppressive actors influence cytotoxic T cell division, and how pharmacological manipulation of this pathway might influence immune response.

**MATERIAL AND METHODS**

**Animals**

VHLfl/fl, LysMCre+, HIF-1αfl/fl, LysMCre+, HIF-2αfl/fl, LysMCre+, Arg-1fl/fl, LysMCre+, Arg-2fl/fl, LysMCre+ were generated by crossing transgenic mice homozygous for loxP-flanked genes of interest (fl/fl) with mice expressing Cre recombinase driven by the lysozyme M promoter (LysMCre+) (15). Transgenic mice heterozygous for Cre recombinase and homozygous for loxP-flanked genes of interest were the conditional knockouts, and compared to littermates carrying only the loxP-flanked gene of interest as wild type controls. Spleens and lymph nodes were harvested from OT-1 mice (003831, The Jackson Laboratory) for isolation of ovalbumin-specific OT-1 CD8+ T cells. All in vivo experiments were approved by the Swedish ethical approval board (Stockholm north, N101/16) and were performed on mice aged between 8-16 weeks. Swedish national guidelines were conformed to in all animal housing and care.

**Cell Lines**

All tumor cell lines were cultured in DMEM (11995065, Gibco) supplemented with 10% FBS (10270106, Gibco) and 1% penicillin/streptomycin. All tumor cell lines were cultured in DMEM (11995065, Gibco) supplemented with 10% FBS (10270106, Gibco) and 1% penicillin/streptomycin and 1% L-glutamine.

B16-F10-OVA were generated through co-transfection of the transposon vector pT2 containing codon-optimized genes for chicken ovalbumin (OVA; P01012.2), eGFP (ABG78037.1), neomycin phosphotransferase (NeoR; BAD00047.1) and the vector encoding transposase SB11.

OVA, eGFP and NeoR were expressed as a polycistronic peptide interspersed with P2A and furin cleavage sites and synthesized by Gene Art (Thermo Fisher). This was then cloned under the promoter SV40 in the transposon vector pT27BH (gift from Perry Hackett, Addgene plasmid #26556). Plasmid containing the sleeping beauty transposase (pCMV-SB11, Addgene plasmid #26552) was a gift from Perry Hackett.

Transfected cells were cultured with 400 mg/mL G418 (10131027, Gibco) three days post transfection in order to select for transfected cells. Transfection success was confirmed through flow cytometry analysis of eGFP fluorescence. Clonal B16-F10-OVA cell line was then produced through limiting dilution.

**Antigen Presenting Assay**

Bone marrow-derived myeloid cells (BMDM) were generated by isolation of bone marrow cells from femur and tibia (16), and cultured for 7 days in DMEM (11995065, Gibco) supplemented with 10% FBS (10270106, Gibco), 1% penicillin/streptomycin (10378016, Gibco), 10ng/mL M-CSF and GM-CSF (416-ML-050/CF and 415-ML-050/CF, R&D Systems). 7 days post isolation, 100ng/mL LPS (L2630, Sigma-Aldrich) was added to culture for 24 hours. For the antigen presenting assay, BMDMs were harvested and incubated with for 1 hour with 100 ng/mL chicken albumin (OVA) derived peptide (SIINFEKL) (S7951, Sigma Aldrich), followed by washing three times with PBS (14190-144, Gibco) and culturing in RPMI (11875085, Gibco) supplemented with 10% FBS, 1% penicillin/streptomycin and 55µM 2-Mercaptoethanol (21985023, Gibco) in 96 well round bottom plates (50 000 cells/well). Surface expression of coactivators and antigen presentation on BMDMs was confirmed by flow cytometry. CD8+ OT-1 T cells were isolated from gender matched OT-1 spleens and lymph nodes by magnetic bead separation (130-104-075, Miltenyi) and stained with CellTrace Violet Cell dye (C34557, Invitrogen), for cell division tracking. The antigen presenting assay was carried out by adding 200 000 T cells to SIINFEKL-loaded BMDM in a 96 well plate. The co-culture was either preformed at atmospheric oxygen conditions (21% O2) or at hypoxic conditions (5% or 1% O2) for three days in a hypoxia workstation (INVIVO2 400, Ruskinn). Cell division and phenotype was assessed by flow cytometry. CD8+ OT-1 T cells cultured in media with 100 ng/mL SIINFEKL were used as positive control.

**Flow Cytometry**

Cell cultures were harvested and stained with Near-IR Dead Cell Stain Kit (L34975, Thermo Fisher) for dead cell exclusion, followed by surface staining with fluorochrome labeled antibodies (Table 1). BD Cytofix/Cytoperm kit (554714, BD Biosciences) was used for cytoplasmic staining of Granzyme B and CTLA-4.

**NOC-18 Treatment**

100 000 CD8+ T cells were activated in 96-well round bottom plates with CD3/CD28 Dynabeads (11453D, Thermo Fisher) in 200uL RPMI supplemented with 10% FBS, 1% penicillin/
streptomycin and 2-Mercaptoethanol and 10U/mL IL-2 in the presence of increasing NOC-18 (ALX-430-014-5005, Enzo) concentrations (12.5, 25, 100, 200 and 400 μM). For cell division tracking, cells were loaded with CTV. 72 hours after activation T cells were analyzed by flow cytometry.

**Tumor Assays**

Transgenic mice were injected with 2x10^5 B16-F10-OVA intravenously by the tail vein. Lungs were perfused with PBS through the left heart ventricle and collected from euthanized mice 21 days post injection of tumor cells. The number of metastatic foci was determined by counting black nodules macroscopically and sized by scoring system.

**Antigen Presenting Assay with FG4592 and DMOG**

For optimization, BMDMs were treated with 100, 50, 25, 12.5, 0 μM FG4592 (HIF prolyl-hydroxylase inhibitor) or hypoxia for 24 hours before collected for transcriptional analysis of iNOS expression using Qiagen RNeasy Kit (cat nr: 74104). cDNA was produced with iScript cDNA Synthesis Kit (1708890, Bio Rad) followed by realtime analysis using KiCqStart SYBR Green predesigned primers (KSPQ12012, Sigma-Aldrich) for Nos2 (GeneID: 18126) and Hprt (GeneID: 15452). The optimal dose of FG4592 was selected by choosing the concentration of FG4592 that induces the same level of Nos2 expression as hypoxia. The antigen presenting assay was performed as described above with either 12.5 μM FG4592 (15294, Cayman Chemical), 12.5 μM DMOG (71210 Cayman Chemical) or Dimethyl sulfoxide (D8418, Sigma-Aldrich) as a solvent control.

**Myeloid Suppression Assay**

BMDMs and CD8+ T cells were acquired and stained (as described above) from transgenic and wildtype mice respectively. CTV stained CD8+ T cells were then activated with Dynabeads Mouse T-Activator CD3/CD28 (Thermo Fisher, Sweden) for 24 hours. Prior to the co-culture with myeloid cells, Dynabeads were removed from CD8+ T cell culture by magnetic separation. Myeloid suppression assay was performed by co-culture of 50 000 LPS activated BMDM with 200 000 activated T cells for 72 hours in a round bottom 96 well plate.

Myeloid suppression assays with human primary cells were performed by isolation of peripheral blood monocytes (PBMC) using Ficoll-Paque PLUS (17-1440-02, GE Healthcare) from

---

**TABLE 1 | Antibodies and stains used for different analyses performed with flow cytometry.**

| Stain name | Antigen | Fluorochrome | Dilution | Clone |
|------------|---------|--------------|----------|-------|
| **Antigen Presenting Assay** | CTV | eFluor 450 | 500 | 53-6,7 |
| | CD8 | Brilliant Violet | 510 | |
| | Live/dead | APC-Cy7 | 200 | 11 |
| | CTLA-4 | PE | 200 | GB12 |
| | GzmB | PE-Cy7 | 400 | IM7 |
| BMDM 1 | Live/dead | APC-Cy7 | 500 | |
| | Fc block | 50 | 93 |
| | CD80 | Pacific Blue | 200 | 16-10A1 |
| | CD86 | Alexa Fluor 488 | 200 | GL-1 |
| | H2KB-OVA | PE | 200 | 25-D1.16 |
| | CD11c | PE-Cy7 | 125 | HL3 |
| | H2KB | Alexa Fluor 647 | 200 | AF6-88.5 |
| BMDM 2 | Live/dead | APC-Cy7 | 500 | |
| | Fc block | 50 | 93 |
| | PD-L1 | PE | 100 | MIH5 |
| | CD11c | PE-Cy7 | 125 | HL3 |
| | MHC Class II | Alexa Fluor 647 | 1600 | MS/114.15.2 |
| **Human Monocyte** | Live/dead | APC-Cy7 | 500 | |
| | Fc block | 50 | |
| | CD16 | Horizon V450 | 200 | 3G8 |
| | CD45 | FITC | 200 | HI30 |
| | CD11b | PE | 200 | M1/70 |
| | CD25 | Alexa Fluor 647 | 200 | M-A251 |
| **Human Ex Vivo Lymphoid** | CTV | eFluor 450 | 500 | |
| | Live/dead | APC-Cy7 | 500 | |
| | Fc block | 50 | |
| | CD8 | BV510 | 200 | SK1 |
| | CD45RA | APC | 100 | HI100 |
| | TCR α/β | PerCP/Cy5.5 | 100 | IP26 |
| | CD45RO | FITC | 100 | UCHL1 |
| | GzmB | PE | 200 | GB12 |

Viability staining was performed using or Near-IR Dead Cell Stain Kit (L34975, Thermo Fisher).
buffy coats provided from Karolinska University Hospital (Stockholm, Sweden). CD8+ T cells and monocytes were isolated by micro bead separation using positive selection for CD8+ T cells (130-045-201, Miltenyi) followed by negative selection for pan-monocytes (130-096-537, Miltenyi). Prior to co-culture of monocytes and CD8+ T cells, 100 ng/mL LPS was added to the monocyte culture, while CD8+ T cells were activated using plate bound Ultra-LEAF Purified anti-human CD3 antibody (clone OKT3, Biolegend). 24 hours post activation monocytes and CD8+ T cells were washed once with complete RPMI cell media and co-cultured for 72 hours in a round bottom 96 well plate (50 000 monocytes and 200 000 CD8+ T cells per well), followed by analysis with flow cytometry. As positive controls activated CD8+ T cells were cultured with plate bound anti-human CD3 antibody with similar treatments and conditions as co-cultured samples. All cell cultures were performed in RPMI supplemented with 10% FBS, 1% penicillin/streptomycin and 55µM 2-Mercaptoethanol.

RESULTS

In order to better understand oxygen-mediated changes in myeloid/lymphoid interactions, we first sought to determine whether increased expression of HIF transcription factors in myeloid cells can drive immunosuppression during antigen-dependent CD8+ T cell activation. We utilized a co-culture system in which myeloid cells present a specific antigen (the ovalbumin-derived OVA peptide) to transgenic CD8+ T cells bearing the OT-I T cell receptor specific for that peptide (OT-I T cells).

We undertook co-culture of bone marrow-derived myeloid cells (BMDMs) which were LPS-activated and loaded with the OVA peptide SIINFEKL. The myeloid cells present antigen through H-2Kb to naïve CD8+ T cells from transgenic mice expressing the OT-1 transgene, specific for the SIINFEKL peptide (this experimental model is outlined in Supplementary Figures 1A–C). As a positive control, OT-1 CD8+ T cells were cultured with SIINFEKL peptide, but without BMDMs. As shown in representative histograms (Supplementary Figure 1D), there were no significant oxygen-dependent effects seen on CD8+ T cell division or activation (Supplementary Figure 1D) detected after three days in this experimental assay.

Previous work from our group has found that T cell proliferation following TCR triggering is suppressed in hypoxia during co-culture with wild type myeloid cells, and found this suppression to be dependent on an intact myeloid cell HIF-1α gene (7). To further examine this, the genetic components of hypoxia-driven suppression of CD8+ T cell division by myeloid cells were determined. As shown in Figure 1A, loss of HIF-1α in myeloid cells increased cell division in co-cultured CD8+ OT-I expressing T cells under both high and low oxygen conditions following activation by antigen presenting myeloid cells. Conversely, loss of HIF-2α (Figure 1A) in myeloid cells had no significant effect on co-cultured antigen activated T cells during either high or low oxygen culture. This indicates that in this experimental system, the key transcriptional effector of myeloid immunosuppression caused by hypoxia is HIF-1α.

We next examined a number of HIF target genes that regulate nitric oxide that are known to induce myeloid immunosuppression of T cell responses (4); these genes can either act to suppress nitric oxide production (Arg1 and Arg2) or induce it (NOS2). Arg1 and Arg2 have been shown to be HIF-2α target genes in myeloid cells, whereas NOS2 is primarily regulated by HIF-1α in these cells (4, 17). Arg1 deletion in myeloid cells (using Arg1fl/fl and Arg1fl/fl LysMCre+ strain mice) results in an insignificant increase in T cell division in high oxygen, with little significant change in division in low oxygen (Figure 1A). However, Arg2 deletion (using Arg2fl/fl and Arg2fl/fl LysMCre+ strain mice) has little effect on T cell division in co-culture (Figure 1A). This is consistent with the lower levels of Arg2 expression seen in myeloid cells relative to Arg1 expression. Interestingly, loss of myeloid cell NOS2 (using NOS2fl/fl and NOS2fl/fl LysMCre+ strain mice) allows increased T cell antigen presentation-induced division in both high and low oxygen conditions relative to co-culture with wild type myeloid cells (Figure 1A).

Loss of myeloid cell HIF-1α caused a post-activation increase in expression of the activation marker Granzyme B on CD8+ T cells during high oxygen co-culture; whereas loss of NOS2 in myeloid cells increased Granzyme B expression under both low and high oxygen co-culture conditions (Figure 1B). As can be seen in Figure 1C, increasing concentrations of an NO donor molecule, NOC-18, effectively suppresses division of activated T cells; this occurs in a dose-dependent manner.

As myeloid cells are known to have an important impact on establishment of metastatic tumors (18), mice with a loss of function of the NOS2 gene in myeloid cells (using NOS2fl/fl and NOS2fl/fl LysMCre+ strain mice) were injected intravenously with OVA expressing B16-F10 cells, a metastatic melanoma cell line. As shown here, mice lacking myeloid NOS2 had decreased numbers of metastatic foci (Figure 1D). This indicates that in this model, myeloid NOS2 expression acts to facilitate metastatic tumor initiation, and may affect overall growth of these tumors, although there was no significant effect of this mutation on metastatic tumor size in these experiments.

To determine whether increased amounts of HIF expression from myeloid cells inhibits T cell division under high oxygen coculture, we employed the antigen presentation conditions described above with CD8+ T cells and myeloid cells with a null mutation in the VHL gene (using VHLfl/fl and VHLfl/fl LysMCre+ strain mice). These mutant mice have increased levels of HIF expression under high oxygen conditions due to diminished oxygen-mediated HIFα degradation. As can be seen in Figure 2A, while wild type myeloid cells suppress T cell division after activation in an oxygen-dependent manner during co-culture, VHL mutant myeloid cells completely suppress T cell division, even under high oxygen conditions.

A number of inhibitors of the prolyl hydroxylase enzymes are currently either in clinical use or under evaluation, primarily for the treatment of anemia (19). These inhibitors act to block hydroxylation of two of the proline residues in the HIF-alpha...
proteins, causing them to become resistant to oxygen-mediated degradation by VHL complexes. As a functional read-out of this effect, we show in Figure 2B that stabilization of HIF by the prolyl hydroxylase inhibitor FG4592 (20, 21) gives rise to a dose-dependent increase in HIF-dependent NOS2 mRNA transcription in primary myeloid cells. In Figure 2B we also show that activated CD8^+ T cells cultured alone or treated with 12.5 micromolar levels of the prolyl hydroxylase inhibitor

FIGURE 1 | Myeloid HIF-1α inhibits antigen induced CD8^+ T-cell division through NOS2. (A) Antigen presenting assay showing representative CTV histograms and division fraction of CD8^+ T-Cells co-cultured with HIF-1α fl/fl (WT) and HIF-1α fl/fl LysMcre+ (HIF-1α KO), HIF-2α fl/fl (WT) and HIF-2α fl/fl LysMcre+ (HIF-2α KO), Arg-1 fl/fl (WT) and Arg-1 fl/fl LysMcre+ (Arg-1 KO), Arg-2 fl/fl (WT) and Arg-2 fl/fl LysMcre+ (Arg-2 KO), NOS2 fl/fl (WT) and NOS2 fl/fl LysMcre+ (NOS2 KO) BMDMs in 21% or 1% oxygen. (B) Expression of Granzyme B as representative histograms and normalized MFI of CD8^+ T-Cells activated by antigen presenting HIF-1α fl/fl vs HIF-1α fl/fl LysMcre+ and NOS2 fl/fl vs NOS2 fl/fl LysMcre+ BMDMs in 21% or 1% oxygen. (C) CD8^+ T-cells activated for 72 hours in 5% O2 and cultured for 2 days with increasing concentration of nitric oxide donor (NO) NOC-18. n=3 donors (D) 10-13 week old mice were injected intra venously with 0.2x10^6 B16-F10-OVA tumor cells. The mice were sacrificed 21 days post injection for collection of lungs. Number of foci and size score NOS2 fl/fl vs NOS2 fl/fl LysMcre+ mice. Data presented as scatter dot plots or violin plots, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; ns, not significant. Statistical analysis was performed with unpaired T test, n= 3-4 bone marrow donors (A, B) and n= 11-15 mice per group (D).
FIGURE 2 | Genetically and compound induced myeloid hypoxia blocks CD8+ T-cell division in vitro. (A) Representative flow cytometry histograms of CTV stained CD8+ T-cells co-cultured with OVA presenting BMDMs in 21%, 5%, 1% oxygen and with BMDMs without Von Hippel-Lindau (VHLfl/fl) in 21% oxygen, division fraction of CD8+ T-cells co-cultured with antigen presenting wildtype BMDMs in different oxygen levels and division fraction of CD8+ T-cells co-cultured with VHLfl/fl (WT) vs VHLfl/fl LysMCre+ (VHL KO) BMDMs in 21% oxygen. (B) NOS2 mRNA expression in BMDMs cultured with increasing concentration of FG-4592 (HIF prolyl-hydroxylase inhibitor) or hypoxia (with ranging values demonstrated as blue shade on y axis) and CD8+ T-cells in a single culture with DMSO or 12.5 µM FG-4592. (C) Antigen presenting assay; BMDM and CD8+ T-cell co-culture treated either with FG-4592 compared to DMSO controls and expression of Granzyme B in CD8+ T-cells in co-culture with BMDMs. (D) Antigen presentation assay performed with NOS2fl/fl or NOS2fl/fl LysMCre+ BMDMs in 21% treated with 12.5 µM FG-4592 or DMOG and co-culture of pre-activated BMDM from NOS2fl/fl or NOS2fl/fl LysMCre+ mice and pre-activated CD8+ T-cells from wildtype mice. Co-cultures were performed in media containing DMSO, 12.5 µM FG-4592 or DMOG. Data presented as scatter dot plots, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, *****P < 0.00001; ns, not significant. Statistical analysis was performed with unpaired T test, n= 4-8 bone marrow donors/group.
**FIGURE 3** | Human monocyte compound induced HIF response blocks human T-cell division in vitro. (A) Illustration of the experimental layout. Human monocytes and CD8+ T-cells were isolated from peripheral blood mononuclear cells and activated with 100 ng/mL LPS and plate bound anti-CD3 antibodies (respectively) for 24 hours. Activation was followed by culturing activated CD8+ T-cells alone or co-culturing CD8+ T-cells with either unstimulated or LPS stimulated monocytes. (B) Percentage divided CD8+ T-cells after three days in three different culturing conditions and treatments; DMSO, 1% O2 or 12.5 µM. All samples presented as the difference to untreated single cultured donor-matched CD8+ T-cells. (C) Expression of Granzyme B in CD8+ T-cells treated as in (B). Data is log2 fold change MFI relative to untreated single cultured donor-matched CD8+ T-cells. Data presented as violin plots or representative histograms, *P < 0.05, **P < 0.01, ***P < 0.001; ns, not significant. Statistical analysis was performed with Two-way RM ANOVA and Tukey’s multiple comparisons test, n = 6 blood donors/group.
continue to proliferate normally. However, as can be seen in Figure 2C, in a co-culture system, the prolyl hydroxylase inhibitor has a strongly inhibitory effect on T cell division. This extends to inhibition of the expression of a number of markers of T cell activation, including Granzyme B, and CTLA4 (Figure 2C).

In order to ascertain whether this myeloid suppression of CD8+ T cell division is NO-dependent, we performed the antigen presenting co-culture assay described above with NOS2 deleted myeloid cells, in combination with one or the other of the prolyl hydroxylase inhibitors FG4592 and DMOG (Figure 2D). We have previously shown that the NOS2 gene is the predominant source for NO in activated murine myeloid cells (4, 7). As shown in Figure 2D, suppression of myeloid NO production via deletion of the myeloid NOS2 gene significantly reduced the myelosuppression caused by these two prolyl hydroxylase inhibitors in co-culture (Figure 2D). This indicates that a key aspect of the myelosuppression caused by pharmacological activation of HIF is NO production by myeloid cells.

As these experiments were all carried out in murine systems, in order to investigate whether these findings are relevant to human cells, we carried out a myeloid suppression assay using human donor peripheral blood monocyte-derived monocytes stimulated ex vivo with LPS (Supplementary Figure 2A) and CD8+ T cells (Supplementary Figure 2B), either in hypoxia, or with FG4592 (Figure 3A). We found that, as with murine CD8+ T cells, FG4592 does not alter CD8+ T cell division in a monoculture of cytotoxic T cells; however, in co-culture with monocytes, FG4592 causes significant suppression of CD8+ T cell division (Figure 3B). Co-cultures of LPS-stimulated monocytes and CD8+ T cells with FG4592 showed suppression of CD8+ T cell expression of the T cell effector molecules Granzyme B (Figure 3C) and CD45RO (Supplementary Figure 2C), while leaving expression of the marker CD45RA unaffected (Supplementary Figure 2D). Overall, this data confirms that FG4592 enhances myeloid cell suppression of CD8+ T cell division and activation in both murine and human primary cell cultures.

**DISCUSSION**

We show here that even intermediate levels of hypoxia can act to trigger myelosuppressive properties in co-culture of myeloid cells with CD8+ T cells. Follow up experiments demonstrated that myeloid inhibition of T cell proliferation was dependent on NO production, specifically through the action of the HIF-1α transcription factor. LPS-stimulated myeloid cells will produce significant amounts of NO even in 21% O2 (23), however, lowering oxygen levels increases nitric oxide production and therefore increases myelosuppression, explaining the observation that even at high oxygen levels, deletion of myeloid HIF-1α or NOS2 allows increased T cell activation and expansion.

Activation of cytotoxic T cells in the presence of the nitric oxide donor NOC-18 suggests that inhibition by NO is dose dependent, reinforcing the hypothesis that the effect of the highly labile NO molecule is strongest when myeloid cells and T cells are in close proximity to one another, such as when an immunological synapse is formed. The reduced numbers of metastases seen here in mice lacking myeloid NOS2 suggest that myeloid NO may contribute to early stages of tumor establishment, particularly as the size of metastatic lesions was not significantly different between wild type and NOS2 mutant mice.

Genetic and pharmacological induction of myeloid HIF-1α (either through deletion of VHL or treatment with FG4592) demonstrated a strong connection between HIF-1α-driven NO production and the ability of myeloid cells to suppress cytotoxic T cell division and activation. As shown in Figure 2D, this myelosuppression is independent of whether T cells are activated independently first, or activated directly in the presence of myeloid cells.

It should be noted that there is extensive evidence for interaction of the NF-kB pathway and HIF and hypoxia (24). An important element for future investigation of the mechanisms of hydroxylase inhibition and the interaction between the innate and adaptive immune system will necessarily need to take this into account. Future studies should help to determine more exactly when hypoxia and HIF activation effect T cell proliferation following antigen presentation and recognition. The timing of these events relative to oxygenation flux will likely be in part dependent on when NF-kB function is itself triggered or suppressed.

Inhibition of PHD activity has been shown to have a potent therapeutic value in models of inflammatory diseases such as colitis (25). Studies have also shown that genetic deletion of PHD-1 in murine models of dextran sulfate sodium (DSS) -induced colitis protected against disease (26). Furthermore, various pharmacological compounds that influence the HIF pathway have demonstrated a protective role in murine models of colitis, and in suppression of disease associated inflammation (27–30). Thus, one possible interpretation of our data is that some of these findings cited above of an anti-inflammatory role for HIF may be due to a HIF-regulated myeloid cell suppression of T cell-induced or -dependent tissue damage.

FG4592 has recently been approved for treatment of anemia in patients suffering from chronic kidney diseases (31). Our data present an interesting and potentially important concern regarding the effects of this and similar drugs on the immune system, and in particular their potential role in modulating myelosuppression.

**DATA AVAILABILITY STATEMENT**

All data involved in this article is available on request from the corresponding author.

**ETHICS STATEMENT**

Animal handling and health monitoring was preformed according to national guidelines for animal care and research.
All experiments in this study have been reviewed and approved by the Stockholm north ethical committee (N101/16).

**AUTHORS CONTRIBUTIONS**

MG, PPC, PV, HR and RJ designed and interpreted the experiments in this study. MG, PPC, GD, LB and PV were involved in data collection. MG, RJ, PV and HR wrote the manuscript. All authors reviewed and approved the final manuscript.

**FUNDING**

This study was funded by the Swedish Research Council (Vetenskapsrådet 2019-01485), the Swedish Cancer Society (Cancerfonden CAN2018/808), the Swedish Children’s Cancer Society (Barncancerfonden PR2020-0075) the Knut and Alice Wallenberg Foundation Scholars Award, and the Wellcome Trust, UK (Principal Research Fellowship 214283/Z/18/Z). PPC was supported by a Portuguese Foundation for Science and Technology (FCT) scholarship (SFRH/BD/115612/2016).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.633586/full#supplementary-material

**REFERENCES**

1. Palazon A, Goldraht AW, Nizet V, Johnson RS. Hif Transcription Factors, Inflammation, and Immunity. *Immunity* (2014) 41(4):518–28. doi: 10.1016/j.immuni.2014.09.008
2. Watts ER, Walmsley SR. Inflammation and Hypoxia: HIF and PHD Isoform Selectivity. *Trends Mol Med* (2019) 25(1):33–46. doi: 10.1016/j.molmed.2018.10.006
3. Cramer T, Yamanishi Y, Clausen BE, Förster I, Pawlinski R, Mackman N, et al. Hif-1alpha is Essential for Myeloid Cell-Mediated Inflammation. *Cell* (2003) 113(5):645–57. doi: 10.1016/S0092-8674(03)01054-5
4. Takeda N, O’Dea EL, Doedens A, Kim JW, Weidemann A, Stockmann C, et al. Differential Activation and Antagonistic Function of HIF-α Isoforms in Macrophages are Essential for NO Homeostasis. *Genes Dev* (2010) 24(5):491–501. doi: 10.1101/gad.1881410
5. Palazon A, Tyriks PA, Macias D, Veliça P, Rundqvist H, Fitzpatrick S, et al. An HIF-1α/Vegf-A Axis in Cytotoxic T Cells Regulates Tumor Progression. *Cancer Cell* (2017) 32(5):689–83.e5. doi: 10.1016/j.ccell.2017.10.003
6. Goda N, Ryan HE, Khadivi B, McNulty W, Rickert RC, Johnson RS. Hypoxia-Inducible Factor 1alpha is Essential for Cell Cycle Arrest During Hypoxia. *Mol Cell Biol* (2003) 23(1):359–69. doi: 10.1098/rmcbr.2003.0369
7. Doedens AL, Stockmann C, Rubinstein MP, Liao D, Zhang N, DeNardo DG, et al. Macrophase Expression of Hypoxia-Inducible Factor-1 Alpha Suppresses T-cell Function and Promotes Tumor Progression. *Cancer Res* (2010) 70(19):7465–75. doi: 10.1158/0008-5472.CAN-10-1439
8. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. *Cell* (2011) 144(5):646–74. doi: 10.1016/j.cell.2011.02.013
9. Lee CT, Maier T, Repasky EA. Hypoxia-Driven Immunosuppression: A New Reason to Use Thermal Therapy in the Treatment of Cancer? *Int J Hyperthermia* (2010) 26(3):232–46. doi: 10.3109/02665673103601745
10. Nomann MZ, Desantis G, Janji R, Hasim M, Karray S, Dessen P, et al. α4β1 is a Novel Direct Target of HIF-1α, and its Blockade Under Hypoxia Enhanced Mds5-Mediated T Cell Activation. *J Exp Med* (2014) 211(5):781–90. doi: 10.1084/jem.20131916
11. Crotty Alexander LE, Akong-Moore K, Feldstein S, Johannson P, Nguyen A, MacEachern EK, et al. Myeloid Cell Hif-1α Regulates Asthma Airway Resistance and Eosinophil Function. *J Mol Med* (2013) 91(5):637–44. doi: 10.1007/s00109-012-0986-9
12. Peyssonnaux C, Datta V, Cramer T, Doedens A, Theodorakis EA, Gallo RL, et al. Hif-1alpha Expression Regulates the Bactericidal Capacity of Phagocytes. *J Clin Invest* (2005) 115(7):1806–15. doi: 10.1172/JCI23863
13. Imtiyaz HZ, Williams EP, Hickey MM, Patel SA, Durham AC, Yuan LJ, et al. Hypoxia-Inducible Factor 2alpha Regulates Macrophage Function in Mouse Models of Acute and Tumor Inflammation. *J Clin Invest* (2010) 120(8):2699–714. doi: 10.1172/JCI39506
14. Susen RM, Bauer R, Olesch C, Fuhrmann DC, Fink AF, Dehne N, et al. Macrophase HIF-2α Regulates Tumor-Suppressive Spint1 in the Tumor Microenvironment. *Mol Carcinog* (2019) 58(11):2127–38. doi: 10.1002/mc.23103
15. Clausen BE, Burkhardt C, Reith W, Renkawitz R, Förster I. Conditional Gene Targeting in Macrophages and Granulocytes Using LysMcre Mice. *Transgenic Res* (1999) 8(4):265–77. doi: 10.1007=A10084928960
16. Liu X, Quan N. Immune Cell Isolation From Mouse Femur Bone Marrow. *Bio Protoc* (2015) 5(20):e1631. doi: 10.21769/BioProtoc.1631
17. Cowburn AS, Crosby A, Macias D, Branco C, Colazo RDDR, Southwood M, et al. Hif2α–Arginase Axis is Essential for the Development of Pulmonary Hypertension. *PNAS* (2016) 113(31):8801–6. doi: 10.1073/pnas.1602978113
18. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. Role of Tumor-Associated Macrophages in Tumor Progression and Invasion. *Cancer Metastasis Rev* (2006) 25(3):215–22. doi: 10.1007/10555-006-9001-7
19. Maxwell PH, Eckardt KL. Hif Prolyl Hydroxylase Inhibitors for the Treatment of Renal Anaemia and Beyond. *Nat Rev Nephrol* (2016) 12(3):157–68. doi: 10.1038/nrnefph.2015.193
20. Besarab A, Provenzano R, Hertel J, Zabaneh R, Klaus SJ, Lee T, et al. Randomized Placebo-Controlled Dose-Ranging and Pharmacodynamics Study of Roxadustat (Fg-4592) to Treat Anemia in Nondialysis-Dependent Chronic Kidney Disease (Ndd-CKD) Patients. *Nephrol Dialysis Transplant* (2015) 30(10):1665–73. doi: 10.1093/ndt/gfv302

21. Provenzano R, Besarab A, Sun CH, Diamond SA, Durham JH, Cangiano JL, et al. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (Fg-4592) for the Treatment of Anemia in Patients With Ckd. *Clin J Am Soc Nephrol* (2016) 11(6):982–91. doi: 10.2215/CJN.06890615

22. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, et al. Targeting of HIF-alpha to the Von Hippel-Lindau Ubiquitylation Complex by O2-regulated Prolyl Hydroxylation. *Science* (2001) 292(5516):468–72. doi: 10.1126/science.1059796

23. Ceciło CA, Costa EH, Simioni PU, Gabriel DL, Tamashiro WM. Aging Alters the Production of Inos, Arginase and Cytokines in Murine Macrophages. *Braz J Med Biol Res* (2011) 44(7):671–81. doi: 10.1590/S0100-879X2011007500067

24. Tafani M, Pucci B, Russo A, Schito L, Pellegrini L, Perrone GA, et al. Modulators of HIF1α and NFkB in Cancer Treatment: Is it a Rational Approach for Controlling Malignant Progression? *Front Pharmacol* (2013) 4:13. doi: 10.3389/fphar.2013.00013

25. Brown E, Taylor CT. Hypoxia-Sensitive Pathways in Intestinal Inflammation. *J Physiol* (2018) 596(15):2985–9. doi: 10.1113/JP274350

26. Tambuwala MM, Cummins EP, Lenihan CR, Kiss J, Stauch M, Scholz CC, et al. Loss of Prolyl Hydroxylase-1 Protects Against Colitis Through Reduced Epithelial Cell Apoptosis and Increased Barrier Function. *Gastroenterology* (2010) 139(6):2093–101. doi: 10.1053/j.gastro.2010.06.068

27. Halligan DN, Khan MN, Brown E, Rowan CR, Coulter IS, Doherty GA, et al. Hypoxia-Inducible Factor Hydroxylase Inhibition Enhances the Protective Effects of Cyclosporine in Colitis. *Am J Physiol Gastrointest Liver Physiol* (2019) 317(2):G90–7. doi: 10.1152/ajpgi.00049.2019

28. Keely S, Campbell EL, Baird AW, Hansbro PM, Shalwitz RA, Kotsakis A, et al. Contribution of Epithelial Innate Immunity to Systemic Protection Afforded by Prolyl Hydroxylase Inhibition in Murine Colitis. *Mucosal Immunol* (2014) 7(1):114–23. doi: 10.1038/mi.2013.29

29. Hindryckx P, De Vos M, Jacques P, Ferdinande L, Peeters H, Olievier K, et al. Hydroxylase Inhibition Abrogates TNF-alpha-induced Intestinal Epithelial Damage by Hypoxia-Inducible Factor-1-Dependent Repression of FADD. *J Immunol (Baltimore Md: 1950)* (2010) 185(10):6306–16. doi: 10.4049/jimmunol.1002541

30. Kim YI, Yi EJ, Kim YD, Lee AR, Chung J, Ha HC, et al. Local Stabilization of Hypoxia-Inducible Factor-1α Controls Intestinal Inflammation Via Enhanced Gut Barrier Function and Immune Regulation. *Front Immunol* (2021) 11:609689. doi: 10.3389/fimmu.2020.609689

31. Dhillon S. Roxadustat: First Global Approval. *Drugs* (2019) 79(5):563–72. doi: 10.1007/s40265-019-01077-1

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2021 Gojkovic, Cunha, Darmasaputra, Barbieri, Rundqvist, Velican and Johnson. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*